biostudies-literaturePedersen CALiaison committee between the Central Norway Health Authority and NTNUStiftelsen Kristian Gerhard JebsenKreftforeningen, NorwayNTNU Norwegian University of Science and TechnologyKreftforeningenThe joint research committee between St. Olavs Hospital and the Faculty of Medicine and Health Sciences, NTNUHorizon 202043https://www.ebi.ac.uk/biostudies/studies/S-EPMC9233373biostudies-literatureUnknown24(1)<h4>Background</h4>Locally advanced breast cancer is a heterogeneous disease with respect to response to neoadjuvant chemotherapy (NACT) and survival. It is currently not possible to accurately predict who will benefit from the specific types of NACT. DNA methylation is an epigenetic mechanism known to play an important role in regulating gene expression and may serve as a biomarker for treatment response and survival. We investigated the potential role of DNA methylation as a prognostic marker for long-term survival (> 5 years) after NACT in breast cancer.<h4>Methods</h4>DNA methylation profiles of pre-treatment (n = 55) and post-treatment (n = 75) biopsies from 83 women with locally advanced breast cancer were investigated using the Illumina HumanMethylation450 BeadChip. The patients recBreast cancer research : BCRDNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.PMC9233373758306202021283286834362Eikesdal HPGiskeodegard GFRye MBLonning PEBathen TFPedersen CAKristensen VNCao MDFleischer TTessem MBKnappskog STost JfalseDNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.<h4>Background</h4>Locally advanced breast cancer is a heterogeneous disease with respect to response to neoadjuvant chemotherapy (NACT) and survival. It is currently not possible to accurately predict who will benefit from the specific types of NACT. DNA methylation is an epigenetic mechanism known to play an important role in regulating gene expression and may serve as a biomarker for treatment response and survival. We investigated the potential role of DNA methylation as a prognostic marker for long-term survival (> 5 years) after NACT in breast cancer.<h4>Methods</h4>DNA methylation profiles of pre-treatment (n = 55) and post-treatment (n = 75) biopsies from 83 women with locally advanced breast cancer were investigated using the Illumina HumanMethylation450 BeadChip. The patients rec2022-01-01T00:00:00Z2022 Jun2025-04-04T19:13:20.221Z2025-04-04T19:13:20.221ZS-EPMC92333733575109510.1186/s13058-022-01537-9